Efficacy of rebamipide combined with rabeprazole in treatment of chronic atrophic gastritis and its impact on gastrointestinal hormones and inflammatory factors
Chen Jing
Qu Cheng-yuan
Ye Qing-long
Abstract：Objective To investigate the efficacy of rebamipide combined with rabeprazole in treatment of chronic atro-phic gastritis and its influences on gastrointestinal hormones and inflammatory factors. Methods A total of 168 patients with chronic atrophic gastritis treated in Zhuhai Hospital of Guangdong Provincial People's Hospital between January 2022 and De-cember 2023 were enrolled in this study. According to the random number table method,they were divided into the experimen-tal group (n=72,treated with rebamipide in combination with rabeprazole) and control group (n=72,treated with rabeprazole alone). All patients in both groups were treated for 2 months. The clinical efficacy,gastrointestinal hormones (calcitonin gene-re-lated peptide (CGRP),gastrin (GAS),epidermal growth factor (EGF)),inflammatory factors (interleukin (IL)-8,IL-11,tumor necrosis factor-α (TNF-α)) and adverse reactions were compared between the two groups. Results The response rate of treat-ment was higher in the experimental group than in the control (91.67％ (66/72) vs 77.78％ (56/72),x2=5.365,P=0.021). Before treatment,there were no significant differences in CCPR,GAS and EGF between experimental group and the control ((27.17±4.28) ng·L-1,(88.12±11.48) pg·mL-1,(4.28±0.47) ng·L-1 vs (26.78±4.37) ng·L-1,(89.16±10.43) pg·mL-1,(4.37±0.56) ng·L-1;t=0.541,P=0.589;t=0.569,P=0.570;t=1.045,P=0.298),but there were significant differences between the two groups after treat-ment ((40.39±5.71) ng·L-1,(131.34±17.42) pg·mL-1,(2.53±0.35) ng·L-1 vs (35.24±4.93) ng·L-1,(117.71±15.49) pg·mL-1,(2.97±0.54) ng·L-1;t=5.793,P<0.001;t=4.961,P<0.001;t=5.802,P<0.001). Before treatment,there were no significant differences in IL-8,IL-11 or TNF-α between the experimental group and the control ((10.96±2.27) ng·L-1,(71.28±7.23) ng·L-1,(68.63±8.49) ng·L-1 vs (10.53±2.21) ng·L-1,(69.33±6.26) ng·L-1,(67.58±9.55) ng·L-1;t=1.152,P=0.251;t=1.730,P=0.086;t=0.697,P=0.487),but there were significant differences between the two groups after treatment ((7.08±1.26) ng·L-1,(41.75±6.27) ng·L-1,(52.87±5.63) ng·L-1 vs (8.37±1.67) ng·L-1,(47.52±6.35) ng·L-1,(58.39±6.54) ng·L-1;t=5.232,P<0.001;t=5.486,P<0.001;t=5.428,P<0.001). No sig-nificant difference in total incidence of adverse reactions was found between the experimental group and the control (11.11％ (8/72) vs 8.33％ (6/72),x2=0.316,P=0.574). Conclusion Rebamipide combined with rabeprazole can improve clinical efficacy,gastrointestinal hormones and inflammatory factors in patients with chronic atrophic gastritis. Meanwhile,it is of high safety.
Keywords：RebamipideRabeprazoleChronic atrophic gastritisGastrointestinal hormoneInflammatory factor
Publication Date：2024-12-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 734-737 )